Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The main protease of the Middle East respiratory syndrome coronavirus (MERS-CoV), also known as Mpro or 3C-like protease (3CLpro), is a cysteine protease crucial for viral replication and pathogenesis. It cleaves the large viral replicase polyproteins pp1a and pp1ab at multiple sites, generating functional non-structural proteins. MERS-CoV Mpro also cleaves cellular substrates like MAVS, suppressing innate immune responses. It functions as a homodimer and is a promising target for antiviral drug development.
Inhibition of MERS-CoV Mpro prevents viral polyprotein processing and replication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Middle East Respiratory Syndrome Coronavirus Main Protease (Mpro).